Safe and Potent Vaccines against Tularemia
- Technology Benefits
- Non-toxic, more stable, and better characterized than LVS vaccine Efficacy is comparable to LVS Highly attenuated in comparison with its LVS parent.
- Technology Application
- Prevent infection caused by Francisella tularensis, the agent of tularemia.
- Detailed Technology Description
- The present innovation consists of a method for producing a vaccine, and a new vaccine for preventing tularemia in humans and animals. This vaccine utilizes a genetically defined attenuated mutant of the F.tularensis Live Vaccine Strain (LVS) to prevent Francisella tularensis infection. Unlike currently used LVS, which is not approved for general use, this new vaccine is non-toxic, stable, and well-characterized.
- Supplementary Information
- Patent Number: US8481024B2
Application Number: US13319024A
Inventor: Horwitz, Marcus A. | Jia, Qingmei | Clemens, Bai-Yu L.
Priority Date: 4 May 2009
Priority Number: US8481024B2
Application Date: 4 Nov 2011
Publication Date: 9 Jul 2013
IPC Current: A61K003902
US Class: 4240932 | 4240934 | 4241841 | 4242001
Assignee Applicant: The Regents of the University of California
Title: Vaccines against tularemia
Usefulness: Vaccines against tularemia
Summary: The live vaccine and immunoprotective composition are useful for inducing protective immunity in a subject and protecting a susceptible host against an infection of F. tularensis (all claimed).
Novelty: Live vaccine useful for inducing protective immunity in a subject and protecting a susceptible host against an infection of Francisella tularensis, comprises Francisella tularensis lacking a polynucleotide encoding CapB
- Industry
- Biomedical
- Sub Category
- Medical Composition
- Application No.
- 8481024
- Others
-
State of Development
The new vaccine has been tested in animals.
Background
Tularemia is a disease caused by the bacterium Francisella tularensis, one of the most infectious pathogenic bacteria known to affect both animals and humans. Although natural infections of F. tularensis have become less of a threat, the ease with which this bacterium can be manufactured and disseminated, its high infectivity, and high mortality when transmitted by the respiratory route remain a major concern. For that reason, the CDC has classified F. tularensis as a Category A bioterrorism agent. This biological agent has long been considered a potential biological weapon, and there are indications suggesting its use during World War II. It is believed that if used as a biological weapon, an aerosol release would have the greatest adverse effect resulting in a highly fatal pneumonia. To protect against potential use of this agent as a bioterrorist weapon, a safe, well-characterized, stable, and effective vaccine against F. tularensis is needed.
Additional Technologies by these Inventors
- New Recombinant Tuberculosis BCG Vaccine for Immunocompromised Patients and Others
- Recombinant Tuberculosis BCG Vaccine Elicits a Highly Protective Host Immune Response
- Method of Producing Novel Unmarked Recombinant Vaccine Vector for Tuberculosis
- Novel Vaccines Against Tularemia
- Improved Immunization Strategy Using Recombinant BCG Vaccines
- Novel Live Recombinant Booster Vaccine against Tuberculosis
- Live Recombinant Tuberculosis Vaccine
Tech ID/UC Case
20456/2009-655-0
Related Cases
2009-655-0
- *Abstract
-
UCLA scientists have developed a method to produce a tularemia vaccine for humans and animals. The currently used vaccine, F.tularensis Live Vaccine Strain (LVS) is toxic, unstable, and poorly characterized. This new vaccine overcomes these major drawbacks.
- *IP Issue Date
- Jul 9, 2013
- *Principal Investigator
-
Name: Bai-Yu Lee Clemens
Department:
Name: Marcus Horwitz
Department:
Name: Qingmei Jia
Department:
- Country/Region
- USA
